SecBot SecBot

APVO

Aptevo Therapeutics Inc.
Nasdaq· Pharmaceutical Preparations· Inc. DE· CIK 0001671584 Biotech & Drug Discovery
$1.73 +0.12 (+7.45%)
Oct 26 4:00 PM ET · prev $1.61
Market cap
$2.9M
Nano cap
Median target
$25.50
+1374% · range $21.00–30.00
Next earnings
Nov 4
in 9 days · EPS est. −$3.54
1 year
−93.6%
from $27.00 · Oct 27
30 days
−9.4%
from $1.91
52-week range
$1.60–28.08
−94% from high · low Oct 19
Avg volume 20D
33.6K
Oct 12 spike 282.3K
Short interest
119.5K
≈6.6% of shares · −36.4%
Days to cover
1.7
at average volume
Insider net
$0
no open-market trades · 12 mo
New fund stakes
0
Q2 2026 13F · 0 exits
Filing reports
11
analyzed by SecBot
SecBot read MIXED 7 reports · 90 days
Balance 1 bearish · 0 bullish · 2 mixed · 4 neutral oldest → newest, height = score
Avg score ·High conf. 4/7 ·Next Earnings date, Nov 4, 2026
Strongest MIXED Aptevo Therapeutics filed an 8-K announcing a 93% clinical benefit rate with its mipletamig triplet in…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersNO TRADES

    No open-market buys or sells in 12 months. Recent filings are awards, exercises and tax withholding.

  • InstitutionsMIXED

    Q2 2026: 0 added (0 new), 1 trimmed or exited.

  • EstimatesRISING

    Current-quarter EPS estimate −$5.960 → −$3.540 over 90 days. 0 up, 1 down in 30 days.

  • Short sellersCOVERING

    Short interest −36.4% to 119.5K shares. 1.7 days to cover, ≈6.6% of shares.

  • TrendDOWNTREND

    12% below its 50-day average. New closing low $1.60 on Oct 21.

Who's buying

13F· Q2 2026
0
new positions
0
exits
FundMoveSharesValue
UBS Group AGNEAR_EXIT730$3.2K
UBS Group AGDOUBLED3,445$14.7K
Hudson Bay Capital Management LPADD935,552$168.2K
BANK OF AMERICA CORP /DE/TRIM77$14.00

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

12-month targets · 2 analysts

Price is below the lowest target. Median implies +1374%.Targets as of Oct 26, 2026.

Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Upcoming
Nov 4, 2026
Earnings date
APVO Q3 2026 Earnings Scheduled — 2026-11-04
Recent
Aug 10, 2026
Earnings date
APVO Q2 2026 Earnings Scheduled — 2026-08-10
May 12, 2026
Earnings date
APVO Q1 2026 Earnings Scheduled — 2026-05-12
Mar 2, 2026
Earnings date
APVO Q4 2025 Earnings After Market Close — 2026-03-02

Insider ledger

Form 4
$0
open-market buys or sells · 12 mo
DateInsiderTypeValue
Aug 6, 2026
Kwon SoYoung
SVP, GC, BD & Corp Affairs
EXERCISE638 sh
Aug 6, 2026
Taylor Daphne
SVP, CFO
EXERCISE638 sh
Aug 6, 2026
Lamothe Jeffrey G.
President and CEO
EXERCISE961 sh
Aug 6, 2026
Harsanyi Zsolt
Director
EXERCISE400 sh
Aug 6, 2026
Niederhuber John
Director
EXERCISE400 sh
Aug 6, 2026
White Marvin L
Executive Chair
TAX W/H$1.7K
Aug 6, 2026
Kunz Barbara Lopez
Director
EXERCISE400 sh
Aug 6, 2026
Abdun-Nabi Daniel
Director
EXERCISE400 sh

Earnings setup

Estimates
Nov 4
reports in 9 days
−$3.54
EPS estimate, this quarter
+41%
estimate change, 90 days
0↑ 1↓
revisions, 30 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$3.54-$3.54–-$3.54+40.6%$0.00
Next Q-$2.68-$2.68–-$2.68+52.4%$0.00
Current FY-$16.02-$16.02–-$16.02+33.6%$0.00
Next FY-$10.40-$10.40–-$10.40+51.5%$0.00

Short side

FINRA· Sep 30, 2026
119,457
shares short
-36.4%
vs prior settlement
1.7
days to cover
≈6.6%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 26, 2026 SEC
🔒 Fresh report (last 24h), subscribers only
Oct 23, 2026 SEC
Aptevo Therapeutics filed an 8-K to amend its shareholder rights plan (poison pill), extending the expiration date by…
8-K — Impact 2/10
Oct 14, 2026 SEC
Aptevo announced a non-clinical scientific presentation of its multispecific CD40-directed platform at the SITC 2026…
8-K — Impact 3/10
Aug 10, 2026 Earnings calendar
APVO Q2 2026 Earnings Scheduled — 2026-08-10
Aug 6, 2026 Insider
Kwon SoYoung acquired via exercise 638 shares
SVP, GC, BD & Corp Affairs
Aug 6, 2026 Insider
Taylor Daphne acquired via exercise 638 shares
SVP, CFO
Aug 6, 2026 Insider
Lamothe Jeffrey G. acquired via exercise 961 shares
President and CEO
Jun 30, 2026 Inst.
UBS Group AG — NEAR_EXIT
730 shares ($3.2K)

SecBot reports

11 filings · 3 bullish · 1 bearish · 2 mixed · 5 neutral
All APVO filing & press-release reports (11)